British Columbia BioHistory

Learn about the scientists behind the discoveries, entrepreneurs,
political leaders, and significant events, people and institutions that are the foundation
of the biotechnology, medical device, pharmaceutical and life science industries
in the province of British Columbia.

Tell us about British Columbia's BioHistory. If you are aware of a notable event, person,
organization/company or accomplishment that we should include,
please e-mail: BioHistory@InfoResource.org

1859 -- Charles Darwin published "The Origin of Species."

In 1859, British naturalist Charles Darwin published "On the Origin of Species by Means of Natural Selection, or the Preservation of Favoured Races in the Struggle for Life" in which he postulated his theory of evolution that explained how the diverse of species on Earth evolved from a simple, singled-celled ancestor.

From 1831-1836, Darwin served as a naturalist aboard the H.M.S. Beagle -- a British science expedition around the world. In South America Darwin discovered fossils of extinct animals that were similar to modern species, and on the Galapagos Islands, located west of Equador, he noticed many variations of plants and animals of the same general type as those in South America. Throughout the expedition Darwin studied plants and animals and collected specimens for further study.

Upon his return to London, Darwin conducted thorough research of his notes and specimens, and out of his study grew several related theories: evolution did occur; evolutionary change was gradual, requiring thousands to millions of years; the primary mechanism for evolution was a process called natural selection; and the millions of species alive today arose from a single original life form through a branching process called "specialization."

Darwin's theory of evolutionary selection holds that variation within species occurs randomly and that the survival or extinction of each organism is determined by that organism's ability to adapt to its environment. Darwin's theory of evolution remains the foundation of modern biology.

Suggested Reading:

1865 -- Gregor Mendel, the father of modern genetics, presents his laws of heredity.

1887 -- Marine Hospital Service Hygienic Laboratory (National Institutes of Health) founded.

The National Institutes of Health (NIH) traces its roots to 1887, when a one-room laboratory was created within the Marine Hospital Service (MHS), predecessor agency to the U.S. Public Health Service (PHS). The MHS was established in 1798 to provide for the medical care of merchant seamen -- charged by Congress with examining passengers on arriving ships for clinical signs of infectious diseases, such as cholera and yellow fever, to prevent epidemics.

During the 1870s and 1880s, scientists in Europe presented compelling evidence that microscopic organisms were the causes of several infectious diseases, and MHS officials closely followed these developments. In 1887, Joseph Kinyoun, a MHS physician trained in the new bacteriological methods, set up a one-room laboratory in the Marine Hospital at Stapleton, Staten Island, New York. Kinyoun called this facility a "laboratory of hygiene" in imitation of German facilities, and within a few months, he identified the cholera bacillus and used his Zeiss microscope to demonstrate it to his colleagues as confirmation of their clinical diagnoses.

The Biologics Control Act enacted in 1902 had major consequences for the Hygienic Laboratory. It charged the laboratory with regulating the production of vaccines and antitoxins, making it a regulatory agency four years before passage of the 1906 Pure Food and Drugs Act. The danger posed by biological products that had emerged from bacteriologic discoveries resulted from their production in animals and their administration by injection. In 1901, thirteen children in St. Louis died after receiving diphtheria antitoxin contaminated with tetanus spores. This tragedy spurred Congress to pass the Biologics Control Act, and between 1903-1907 standards were established and licenses issued to pharmaceutical firms for making smallpox and rabies vaccines, diphtheria and tetanus antitoxins, and various other antibacterial antisera. (In 1972, responsibility for regulation of biologics was transferred to the Food and Drug Administration). (Photo: courtesy of the NIH Almanac)

In 1912 MHS was reorganized, renamed the Public Health Service (PHS) and authorized to conduct research into noncontagious diseases and into the pollution of streams and lakes in the U.S. During World War I, the PHS attended primarily to sanitation of areas around military bases in the U.S., and when the 1918 influenza pandemic struck Washington, physicians from the laboratory were pressed into service treating patients in the District of Columbia because so many local doctors had fallen ill. In 1930, the Ransdell Act changed the name of the Hygienic Laboratory to the National Institute of Health (NIH) and authorized the establishment of fellowships for research into basic biological and medical problems. The roots of this act extended to 1918, when chemists who had worked with the Chemical Warfare Service in World War I sought to establish an institute in the private sector to apply fundamental knowledge in chemistry to problems of medicine. In 1937, the National Cancer Institute (NCI) was created with sponsorship from every Senator in Congress, and was authorized to award grants to nonfederal scientists for research on cancer and to fund fellowships at NCI for young researchers.

During World War II, the NIH focused almost entirely on war-related problems. At the close of the war, PHS leaders guided through Congress the 1944 Public Health Service Act, which defined the shape of medical research in the post-war world. Two provisions were especially important: 1) In 1946 the NCI grants program was expanded to the entire NIH, and the program grew from just over $4 million in 1947, to more than $100 million in 1957, and to $1 billion in 1974. The entire NIH budget expanded from $8 million in 1947 to more than $1 billion in 1966, now fondly remembered as "the golden years" of NIH expansion. Accompanying growth in the grants program was the proliferation of new categorical institutes, and from 1946-1949, voluntary health organizations moved Congress to create institutes for research on mental health, dental diseases, and heart disease. In 1948, language in the National Heart Act made the name of the umbrella organization the National Institutes of Health. 2) The 1944 PHS Act authorized NIH to conduct clinical research, and after the war Congress provided funding to build a research hospital, now called the Warren Grant Magnuson Clinical Center on the NIH campus in Bethesda, Maryland. The Center which opened in 1953 with 540 beds was designed to bring research laboratories into close proximity with hospital wards in order to promote productive collaboration between laboratory scientists and clinicians. (Photo: National Archives and Records Administration photograph, courtesy of the Franklin Delano Roosevelt Library, Hyde Park, New York)

The NIH today, part of the U.S. Department of Health and Human Services, is the primary Federal agency for conducting and supporting medical research and is composed of 27 Institutes and Centers, providing leadership and financial support to researchers in every state and throughout the world.

1899 -- Charles E. Frosst & Co founded.

Charles E. Frosst & Co, was founded in 1899 by Mr. Frosst and four associates in 1899, who rapidly introduced new products such as the famous numbered analgesics known as 217® and 222® — products that are still used in Canada. During the 1920s, the company became family-owned and developed a reputation for innovation. During the mid-forties, Charles Frosst pioneered nuclear medicine in Canada by developing the country's first radioactive pharmaceutical products, for sale in Canada and abroad.

In 1965, Merck & Co., Inc. of New Jersey acquired Charles E. Frosst & Co. In 1968, Merck Frosst Laboratories was created to act as the service company to the two sales companies: Merck Sharp & Dohme Canada Limited; and Charles E. Frosst & Co. In 1982, the three companies were restructured under the name Merck Frosst Canada Inc. and it became a fully integrated pharmaceutical company. The company later changed its name to Merck Frosst Canada Ltd.

Today, Merck Frosst, headquartered in Montreal, is one of Canada 's leading research-based pharmaceutical companies and possesses a long record of innovation. The company employs nearly 1,600 people, including more than 300 of the world's leading scientific personnel. The Merck Frosst Centre for Therapeutic Research, one of the largest biomedical research facilities in Canada, has the mandate to discover new therapies for the treatment of respiratory diseases, inflammatory diseases, diabetes and osteoporosis.

1908 -- The University of British Columbia founded.

The University of British Columbia (UBC) was founded in 1908 by The University Act. In 1910 a site was chosen at Point Grey just outside Vancouver, but the university had to postpone building due to the outbreak of way in 1914. The school used the former McGill college site in Fairview until 1925.

Today the university enrolls over 40,000 students and holds an international reputation for excellence in advanced research and learning. The university has three campuses within the city of Vancouver as well as a small campus in Kelowna, BC called UBC Okanagan.

UBC ranks in the top 10 of universities in North America creating spin-off companies with over 120 companies formed.

1918 -- Spanish Influenza Pandemic.

It is estimated that between 25 and 40 million people died from the the influenza outbreak that began in 1918, swept across America in a week and around the world in three months. In all, between 500,000 and 700,000 Americans --civilians and soldiers-- died from the influenza, more than were lost in World War I, II, and the Korean and Viet Nam wars combined.

Latest Findings: In September 2004, the National Institutes of Health (NIH) awarded a five-year, $12.5 million grant to five institutions that will collaborate to study genes constructed from 1918 flu-virus particles salvaged from the bodies of World War I soldiers and the exhumed Brevig Mission, Alaska resident. The Institutions include the Armed Forces Institute of Pathology, Washington, D.C.; Mount Sinai School of Medicine, New York; Scripps Research Institute, La Jolla, CA; the Centers for Disease Control and Prevention; and the University of Washington. The ultimate goal is to use knowledge gained from the study to develop vaccines, influenza medications and diagnostic tests to prevent a similar influenza outbreak.

Suggested Reading:

1933 -- Thomas Hunt Morgan awarded Nobel Prize in Physiology or Medicine for his chromosome theory of heredity.

1947 -- Transistor invented at AT&T's Bell Laboratories.

The transistor, the invention that marked the dawn of the information age, was invented by John Bardeen, William Shockley and Walter Brattain at AT&T's Bell Laboratories. Bardeen, Shockley and Brattain were awarded the 1956 Nobel Prize in Physics for their discovery of the transistor effect.

Transistors have become an invisible technology that is part of almost every electronic device. Every major information age innovation was made possible by the transistor and its application can be found all around us. (Photos: © The Nobel Foundation)

1953 -- Double helix structure of DNA revealed.

The double helix structure of DNA, the hereditary molecule is revealed by two scientists, James D. Watson and Francis Crick. This is one of the key discoveries of the century. Watson and Crick shared the 1962 Nobel Prize for Physiology and Medicine with Maurice Wilkins for their discoveries concerning the molecular structure of nuclear acids and its significance for information transfer in living material.

Rosalind Franklin, whose work contributed to the discovery, died before this date and the rules do not allow a Nobel Prize to be awarded posthumously. (Photos: © The Nobel Foundation)

Suggested Reading:

1958 -- Integrated circuit invented.

1961 -- President John F. Kennedy expands U.S. Space Program

1969 -- Man walks on the moon.

An important benefit of the Apollo Lunar Program and other NASA programs is the ever-growing pipeline of technology that improves human and veterinary healthcare diagnostics and therapeutics.

1969 -- Victor McKusick publishes "Mendelian Inheritance in Man".

Victor McKusick, widely acknowledged as the father of medical genetics, spent his career studying the genetic basis of diseases and disorders with the belief that such an understanding could lead to new methods of diagnosis and treatment. He studied, identified, and mapped genes responsible for inherited conditions such as Marfan syndrome and dwarfism (specifically in Amish communities). In 1969, he proposed the idea of mapping the human genome, over 30 years before the Human Genome Project was established.

McKusick, a graduate of Johns Hopkins (M.D. 1946), spent his entire career there and founded the Division of Medical Genetics in 1957, the first research center and clinic of its kind. In 1969 he published the 1st edition of his book "Mendelian Inheritance of Man", one of the most comprehensive collections of inherited disease genes. In 2002, McKusick received the highest scientific honor in the U.S., the National Medal of Science.

1971 -- NASDAQ Stock Market founded.

Nasdaq, founded February 8, 1971, is now the largest U.S. electronic stock market. With approximately 3,300 companies, it lists more companies and, on average, trades more shares per day than any other U.S. market. NASDAQ is home to companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media, biotechnology, medical device, and pharmaceutical.

Suggested Reading:

1973 -- Recombinant DNA perfected.

1974 -- Employee Retirement Income Security Act of 1974 (ERISA).

John N. Erlenborn, the ranking Republican on the House Committee, was responsible for bringing the Employee Retirement Income Security Act of 1974 (ERISA) to a floor vote, and is one of the ERISA’s "Founding Fathers." Together with Senator Jacob Javits (R-NY), Senator Pete Williams (D-NJ) and Congressman John Dent (D-PA), Erlenborn crafted provisions and participated in negotiations that were instrumental to the enactment of ERISA which was - and remains - the single most important legislation governing employee benefit plans in the United States providing an important source of financial investment for the stock market. (Photos: Jacob Javits and Pete Williams courtesy U.S. Senate Historical Office).

1975 -- Monoclonal antibodies produced.

In 1975, Georges Köhler and César Milstein, showed how monoclonal antibodies can be generated by isolating individual fused myeloma cells.

The 1984 Nobel Laureate in Medicine was awarded jointly to: Niels Jerne, Georges Köhler and César Milstein for theories concerning the specificity in development and control of the immune system and the discovery of the principle for production of monoclonal antibodies. (Photos: © The Nobel Foundation)

1976 -- Genentech, founder of the biotechnology industry, established.

In 1976, Genentech was founded by venture capitalist Robert Swanson and biochemist Dr. Herbert Boyer. In the early 1970s, Boyer and geneticist Stanley Cohen at Stanford University pioneered recombinant DNA technology. Excited by the breakthrough, Swanson called Boyer who agreed to give the young entrepreneur 10 minutes of his time. Swanson's enthusiasm for the technology resulted in a three hour meeting and at its conclusion, Genentech was born.

Within a few short years Swanson and Boyer invented a new industry - biotechnology. In 1980, Genentech issued its Initial Public Offering (IPO) and raised $35 million with an offering that jumped from $35 a share to a high of $88 after less than an hour on the market. The event was one of the largest stock run-ups ever, and that event set the stage for future biotechnolgy industry offerings.

Genentech was initially broadly focused in three areas including food processing, industrial chemicals, and human health care. In 1982, Eli Lilly & Co. which had acquired worldwide rights to Genenetch's recombinant human insulin (1978) received FDA approval to market the product -- the first biotechnology therapeutic to reach the marketplace.

Beginning in 1983, Genentech became solely focused on human therapeutics and diagnostics, and in 1985, Genentech received approval from FDA to market its first product, Protropin® (somatrem for injection) growth hormone for children with growth hormone deficiency — the first recombinant pharmaceutical product to be manufactured and marketed by a biotechnology company. In 1990, Genentech and Roche Holding Ltd. of Basel, Switzerland completed a $2.1 billion merger. Today, Genentech is among the world's leading biotech companies with multiple protein-based products on the market for serious or life-threatening medical conditions.

1977 -- First human gene cloned.

Walter Gilbert induced bacteria to synthesize insulin and interferon, and Frederick Sanger published the complete sequence of phage FX174. The 1980 Nobel Laureate in Chemistry was awarded jointly to Frederick Sanger and Walter Gilbert for "for their contributions concerning the determination of base sequences in nucleic acids, and to Paul Berg for his fundamental studies of the biochemistry of nucleic acids, with particular regard to recombinant-DNA. (Photos: © The Nobel Foundation)

1980 -- U.S. Supreme Court ruled man-made organism patentable.

1980 -- Bayh-Dole Act provides for university technology transfer.

1990 -- Human Genome Project established.

The U.S. Human Genome Project was established -- a 13-year effort coordinated by the U.S. Department of Energy and the National Institutes of Health. The project, originally planned to last 15 years, was expected to be completed by 2003 due to rapid technological advances.

1991 -- LifeSciences British Columbia (BC Biotech) founded.

LifeSciences British Columbia , formerly known as BC Biotech and founded in 1991, supports and represents the biotechnology, medical device, and greater life sciences community of British Columbia through leadership, advocacy and promotion of the industry.

1993 -- Kary B. Mullis awarded Nobel Prize in Chemistry.

1993 -- Michael Smith awarded Nobel Prize in Chemistry.

1999 -- Canada's Michael Smith Genome Science Centre founded.

In 1999, Michael Smith, recipient of the 1993 Nobel Prize in Chemistry, founded the Genome Sciences Centre in British Columbia. The center performs high-throughput genome mapping and DNA sequencing to determine genetic codes, specifically to further cancer research, diagnosis, and treatment.

In 2003, researchers at the centre were the first to sequence the SARS genome, an important step in the development of a potential treatment and vaccine.

2000 -- Genome British Columbia founded.

Genome British Columbia, founded in 2000, is one of six Genome Canada centres across the country. Genome Canada is the primary funding and information resource related to genomics and proteomics in Canada.

Genome British Columbia is a research organization that invests in and manages large-scale genomics and proteomics research projects and science and technology platforms focused on areas of strategic importance such as human health, forestry, fisheries, ethics, agriculture and the environment. By working collaboratively with all levels of government, universities and industry, Genome BC is the catalyst for a vibrant, genomics-driven life sciences cluster with far reaching social and economic benefits for the province and Canada.

2001 -- Human Genome Project draft sequence published.

2008 -- British Columbia BioEvolution illustrates the technology origins of state's industry.

Other Resources

Other State & Province BioHistories

Other Life Science History Resources

Tell us about British Columbia's BioHistory. If you are aware of a notable event, person,
organization/company or accomplishment that we should include,
please e-mail: BioHistory@InfoResource.org